Ranbaxy shares fall after settlement with Pfizer
June 19th, 2008 - 9:44 pm ICT by IANS ( Leave a comment )
Mumbai, June 19 (IANS) The share price of India’s leading drugmaker Ranbaxy Laboratories fell by nearly eight percent following the settlement with Pfizer on a patent dispute. The stock ended down 7.68 percent at the Bombay Stock Exchange at Rs.598.20 after touching a low of Rs.548.10 and a high of Rs.613.70.
On Wednesday, Pfizer said Ranbaxy can start selling a US generic form of its cholesterol drug Lipitor by late 2011.
- Ranbaxy approved to make first generic version of Lipitor - Dec 01, 2011
- Ranbaxy ordered to improve India, US plants - Jan 26, 2012
- Cholesterol Drug Lipitor Recalled By Pfizer Inc. For The Third Time - Oct 31, 2010
- Ranbaxy's June quarter net profit falls by 25 pc - Aug 05, 2011
- Ranbaxy sales may double by 2011 on Pfizer settlement - Jul 29, 2008
- Sensex ends flat, markets shrug off rate hike (Roundup) - Nov 02, 2010
- Ranbaxy shares dip as US blocks import of its 30 drugs (Lead) - Sep 17, 2008
- Ranbaxy Q3 2010 profit up 168 percent - Nov 11, 2010
- Sensex slumps 24 percent in 2011 (Roundup) - Dec 30, 2011
- Sensex continues to trade lacklustre, RIL soars (Lead) - Jan 18, 2012
- Ranbaxy reports Rs.464.6 crore net loss - Nov 09, 2011
- Ranbaxy posts $210 mn net profit - May 11, 2010
- Sensex down 112 points, capital goods, bank stocks hit (Roundup) - Dec 19, 2011
- Pfizer Inc. Broadens Lipitor Recall Over 'Uncharacteristic' Odor - Dec 23, 2010
- Reliance Capital total income up 18 percent - Aug 13, 2011
Tags: bombay stock exchange, cholesterol, cholesterol drug, drug lipitor, India, lipitor, mumbai, patent dispute, pfizer, ranbaxy laboratories, ranbaxy shares, share price
